Nyffenegger R, Riebenfeld D, Bandau K H, Nouri M E, Schirmböck U, Streppel M
ENT University, Köln.
J Chemother. 1993 Dec;5(6):512-6.
To compare the efficacy and safety of brodimoprim (BDP) with those of amoxicillin (AMX) in patients with acute bacterial pharyngitis/tonsillitis.
Randomized controlled study.
Hospital and general practices in Austria, Germany and Switzerland.
519 adult patients of both sexes aged 12 to 75 years.
Patients were allocated to an 8- to 12-day treatment with BDP (400 mg loading dose followed by 200mg once a day) or AMX (750mg t.i.d).
Resolution of clinical signs/symptoms and negative bacterial examination at completion of therapy.
Clinical cure/improvement rate of 97.8% and 94.8% in respectively the BDP and the AMX group. Bacterial eradication in 87.7% of the cases treated with BDP and 88.3% of those receiving AMX. Very good/good tolerability in 85.2% BDP- and 82.8% AMX treated patients.
比较溴莫普明（BDP）与阿莫西林（AMX）治疗急性细菌性咽炎/扁桃体炎患者的疗效和安全性。
随机对照研究。
奥地利、德国和瑞士的医院及普通诊所。
519例年龄在12至75岁之间的成年男女患者。
患者被分配接受为期8至12天的BDP治疗（400mg负荷剂量，随后每天200mg）或AMX治疗（750mg，每日三次）。
治疗结束时临床体征/症状的缓解及细菌检查结果为阴性。
BDP组和AMX组的临床治愈率/改善率分别为97.8%和94.8%。接受BDP治疗的病例中87.7%细菌清除，接受AMX治疗的病例中88.3%细菌清除。BDP治疗患者中85.2%、AMX治疗患者中82.8%耐受性良好/良好。
